Novo Nordisk sales and marketing update

Novo Nordisk launched Novoeight turoctocog alfa in the U.S. to treat hemophilia A. The recommended dosage of the third-generation IV recombinant Factor Vlll ( rFVIII) depends on a patient’s body weig...